John Obell, MD
Nephrology · Riverside, RINPI 1982657805
Payments from drug & device makers
What this record shows
AstraZeneca accounts for 66.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $778 and has fallen 69.0% since, to $241 in 2024.
Across 18 payments — averaging $84.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$163
- Travere Therapeutics, Inc.$137
- Otsuka America Pharmaceutical, Inc.$104
- Akebia Therapeutics Inc$68
- Amgen$33
What the payments were for
- Consulting fees$77851%
- Food & beverage$73849%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $1,011 |
| GSK | 6 | $163 |
| Travere Therapeutics, Inc. | 2 | $137 |
| Otsuka America Pharmaceutical, Inc. | 1 | $104 |
| Akebia Therapeutics Inc | 3 | $68 |
| Amgen | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,516 in reported general payments places this provider in the 60th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $27,871 |
| Sevelamer Carbonate | 43 | $9,789 |
| Calcium Acetate | 32 | $4,480 |
| Torsemide | 75 | $1,404 |
| Eplerenone | 12 | $1,072 |
| Hydroxychloroquine Sulfate | 13 | $643 |
| Midodrine Hcl | 22 | $548 |
| Lisinopril | 53 | $476 |
| Calcitriol | 15 | $454 |
| Amlodipine Besylate | 82 | $404 |
| Amiloride Hcl | 15 | $380 |
| Losartan Potassium | 50 | $357 |
| Pantoprazole Sodium | 15 | $350 |
| Chlorthalidone | 20 | $343 |
| Furosemide | 43 | $343 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Riverside
- Reginald GohhRiverside$47K
- Ankur ShahRiverside$27K
- Jie TangRiverside$23K
- Douglas SheminRiverside$22K
- Kristen TillquistRiverside$2K
- Basma MerhiRiverside$2K
- Sandipan ShringiRiverside$1K
- George BaylissRiverside$246
- Susie HuRiverside$205
- Matthew LynchRiverside$180
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.